Long­time Am­gen leader David Reese is re­tir­ing at the end of June, Am­gen an­nounced Wednes­day evening.

Reese, 63, cur­rent­ly serves as chief tech­nol­o­gy of­fi­cer, a role he cre­at­ed at Am­gen in 2023. Since then, he has led the com­pa­ny’s adop­tion of AI, es­pe­cial­ly as a key part of drug de­vel­op­ment.

Be­fore his time as chief tech­nol­o­gy of­fi­cer, Reese was head of R&D be­gin­ning in 2018. He joined Am­gen in 2005 as a clin­i­cal de­vel­op­ment leader in on­col­o­gy.

Reese told End­points News in 2025 that when he pitched the chief tech­nol­o­gy role, he be­lieved it was "the hinge mo­ment" for AI.

"Dave rec­og­nized ear­ly the im­pact that ad­vances in bi­ol­o­gy and tech­nol­o­gy would have on our in­dus­try and helped lead Am­gen through that shift," Am­gen CEO Bob Brad­way said in a press state­ment.

No­vo Nordisk’s GLP-1 pill works in kids with di­a­betes: Type 2 di­a­betes pa­tients aged 10 to 17 who took Ry­bel­sus for about six months had a sta­tis­ti­cal­ly sig­nif­i­cant 0.83% cut in their blood sug­ar lev­els com­pared with place­bo, No­vo said Thurs­day. The com­pa­ny plans to sub­mit the Phase 3a da­ta to reg­u­la­tors in pur­suit of a la­bel ex­pan­sion in this new pop­u­la­tion. — Eliz­a­beth Cairns

Al­tim­mune’s $225M of­fer­ing: The Mary­land biotech priced its pub­lic of­fer­ing on Wednes­day night to help bankroll its up­com­ing Phase 3 in MASH. The com­pa­ny’s stock price ALT was down 17% in pre-mar­ket trad­ing on Thurs­day. — Kyle LaHu­cik

Mer­ck teams with Google Cloud: The New Jer­sey drug gi­ant will work with the tech be­he­moth to bol­ster its “dig­i­tal back­bone” via a mul­ti-year in­vest­ment “val­ued at up to $1 bil­lion.” The phar­ma said the al­liance will dig­i­tize da­ta and “help boost pro­duc­tiv­i­ty” among the com­pa­ny’s 75,000 glob­al em­ploy­ees. — Kyle LaHu­cik

Roche still has high sales hopes for its breast can­cer pill giredestrant de­spite the drug’s fail­ure in a first-line tri­al ear­li­er this year.

CEO Thomas Schi­neck­er said Thurs­day that the drug could reach three times as many pa­tients as Roche's breast can­cer block­buster Her­ceptin, which at its peak in 2018 had sales of about $7 bil­lion.

Giredestrant is await­ing ap­proval in the US as a sec­ond-line ther­a­py for cer­tain metasta­t­ic breast can­cer pa­tients, with an ini­tial de­ci­sion due in De­cem­ber. Roche has al­so just sub­mit­ted it for ap­proval for use af­ter surgery in cer­tain pa­tients with ear­ly breast can­cer. The com­pa­ny used a pri­or­i­ty re­view vouch­er for this fil­ing, which could mean an­oth­er ap­proval will al­so come this year.